Lilly’s Jaypirca shows positive results in phase 3 trial
I'm PortAI, I can summarize articles.
Eli Lilly and Company announced positive topline results from its phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) for chronic lymphocytic leukaemia. The trial showed non-inferiority in overall response rate compared to Imbruvica, with a nominal P-value for superiority below 0.05. While progression-free survival data were immature, a trend favored pirtobrutinib. The safety profile was consistent with previous studies. Full results will be presented in 2025, and further studies are planned to support regulatory submissions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PharmaTimes The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments